Skip to content

ANTX - AN2 Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchA

AN2 Therapeutics Inc

ANTX · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

A

ANTXAN2 Therapeutics Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $7.19
52-wk low: $1.00
Prev close: $4.22
Mkt cap: $224.9M
Beta: -0.99
P/B: 3.0x

Smart money

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$29.8M

MI
Millennium
Israel Englander · Q2 2026 13F
$11.2M
position
CI
Citadel

Earnings

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $225M

Valuation

P/B2.97

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: ANTX
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $224.91M
Beta: -0.99

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-50.1%

Ken Griffin · Q2 2026 13F

$4.6M

position

BA

Balyasny

Dmitry Balyasny · Q2 2026 13F

$2.7M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for ANTX

No recent Congress trade
No recent market-voice mention

The latest quarter is still settling.

A verdict appears once the reported figure is final

Next report

What the street expects next

EPS expected

-$0.26

-$0.27 to -$0.24

Revenue expected

$0.00

2 analysts

Last 30 days

0up1down

Analysts cutting estimates

Estimate drift

0.02

Change in 30 days

-50.1%

ROA-30.8%

Growth

Beta-0.99